| Ident. | Authors (with country if any) | Title |
|---|
| 000006 |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
| 000279 |
Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada] | Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects |
| 000422 |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
| 000493 |
Moonhee Lee [Canada] ; Claudia Schwab [Canada] ; SHENG YU [Canada] ; Edith Mcgeer [Canada] ; Patrick L. Mcgeer [Canada] | Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide |
| 000922 |
J. G. Nutt [États-Unis] ; K. J. Burchiel [États-Unis] ; C. L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; A. E. Lang [Canada] ; E. R. Jr Laws [États-Unis] ; A. M. Lozano [Canada] ; R. D. Penn [États-Unis] ; R. K. Jr Simpson [États-Unis] ; M. Stacy [États-Unis] ; G. F. Wooten [États-Unis] | Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD |
| 000967 |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis |
| 000A21 |
Sophie Callier [France, Canada] ; Maryvonne Le Saux [France] ; Anne-Marie Lhiaubet [France] ; Thérèse Di Paolo [Canada] ; William Rostene [France] ; Didier Pelaprat [France] | Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture |
| 000A22 |
Michel Cyr [Canada] ; Frederic Calon [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease |
| 000A29 |
C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada] | Dopamine agonist monotherapy in Parkinson's disease |
| 000A34 |
Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada] | Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity |
| 000A78 |
Doris J. Doudet [Canada] | Monitoring disease progression in Parkinson's disease |
| 000B15 |
Moussa B. H. Youdim [Israël] ; Edna Grünblatt [Israël] ; Yona Levites-Royak [Israël] ; Silvia Mandel [Israël] | Drugs to prevent cell death in Parkinson's disease: Neuroprotection against oxidative stress and inflammatory gene expression |
| 000B63 |
Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada] | R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition |
| 000C33 |
A. F. Miranda [Canada] ; M. A. Sutton [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] ; R. J. Boegman [Canada] | Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus |
| 000C45 |
D. L. Gelowitz [États-Unis] ; I. A. Paterson [Canada] | Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration |
| 000D29 |
P. H. Yu [Canada] ; X. Zhang [Canada] ; D. M. Zuo [Canada] ; C. T. Lai [Canada] ; K. Tieu [Canada] ; B. A. Davis [Canada] ; A. A. Boulton [Canada] | Aliphatic N-methylpropargylamines as potential neurorescue agents |
| 000D61 |
A. F. Miranda [Canada] ; R. J. Boegman [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] | Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid |
| 000D77 |
C. Thiffault [Canada] ; L. Lamarre-Theroux [Canada] ; R. Quirion [Canada] ; J. Poirier [Canada] | L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse |
| 000F00 |
P. H. Yu [Canada] | Pharmacological and clinical implications of MAO-B inhibitors |
